Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of Dorzagliatin in Healthy Males
NCT03158506Phase 1Completed
- Sponsor
- Hua Medicine
- Start
- Mar 2017
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dorzagliatin in type 2 diabetes mellitus (T2DM), sponsored by Hua Medicine. Primary endpoint: Total radioactivity in blood, plasma, urine and feces up to 168 hours. Started Mar 2017; status: completed.
02
Drugs
dorzagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03158506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03158506.